<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310229</url>
  </required_header>
  <id_info>
    <org_study_id>AssiutUn</org_study_id>
    <nct_id>NCT03310229</nct_id>
  </id_info>
  <brief_title>Pulmonary Hypertension in Haemodialysis Patients :Frequency and Risk Factors</brief_title>
  <official_title>Pulmonary Hypertension in Haemodialysis Patients :Frequency and Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High mortality rates due to cardiovascular disease in end-stage renal disease patients been&#xD;
      described by epidemiological and clinical studies. It accounts for approximately 50 percent&#xD;
      of deaths in dialysis patients. Although controversial, this may be due to the presence of&#xD;
      excess vascular calcification particularly in the form of extensive coronary artery&#xD;
      calcification which can be observed even in very young dialysis patients. It was suggested&#xD;
      that abnormalities of the right ventricular function in patients with end-stage renal disease&#xD;
      were largely due to pulmonary hypertension which usually develops secondary to pulmonary&#xD;
      artery calcifications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary whose mechanisms are incompletely known, is another vascular disease entity recently&#xD;
      described in chronic kidney disease particularly in patients undergoing haemodialysis. It&#xD;
      corresponds to 5th subtype of World Symposium on Pulmonary Hypertension classification&#xD;
      established in 2008 in Dana Point and updated in 2013 in Nice. Pulmonary hypertension is&#xD;
      defined by Pulmonary arterial pressure mean ≥25 mm Hg at rest measured by right heart&#xD;
      catheterization. Its pathophysiological mechanism is controversy maybe explained by vascular&#xD;
      calcification, blood flow in arteriovenous fistula and fluid overload. Primary pulmonary&#xD;
      hypertension is a major problem of haemodialysis patients because of its high prevalence,&#xD;
      sometimes reaching 68% and by its significant morbidity and mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Actual">December 2, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of pulmonary arterial pressure</measure>
    <time_frame>Pulmonary arterial pressure can be measured for a participant using echocardiography in less than one hour</time_frame>
    <description>The participants will be subjected to a trans-thoracic echocardiography to measure pulmonary arterial pressure to detect and know the frequency of pulmonary hypertension in our haemodialysis patients for adequate care and early treatment and to study its possible risk factors to decrease morbidity and mortality.</description>
  </primary_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>plain chest x-ray</intervention_name>
    <description>the participants will be subjected to plain chest x-ray with other tools to help diagnose pulmonary hypertension in haemodialysis patients</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        80 subjects undergoing haemodialysis for more than one year will be subjected to some&#xD;
        diagnostic tools to detect and know the frequency of pulmonary hypertension(PH) among those&#xD;
        patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  80 haemodialsis patients aged from 18 to 60 years old&#xD;
&#xD;
          -  80 haemodialysis patients are on regular haemodialysis for more than one year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All patients with a high probability of secondary pulmonary hypertension, those with&#xD;
             the following history: chronic obstructive pulmonary disease, pulmonary embolism&#xD;
             congenital heart disease, heart failure, Bilharziasis plus active HIV infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed abbass</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut uni</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41. doi: 10.1016/j.jacc.2013.10.029. Review. Erratum in: J Am Coll Cardiol. 2014 Feb 25;63(7):746. Erratum in: J Am Coll Cardiol. 2014 Feb 25;63(7):746.</citation>
    <PMID>24355639</PMID>
  </reference>
  <reference>
    <citation>Nitta K, Ogawa T. Vascular calcification in end-stage renal disease patients. Contrib Nephrol. 2015;185:156-67. doi: 10.1159/000380980. Epub 2015 May 19. Review.</citation>
    <PMID>26023025</PMID>
  </reference>
  <results_reference>
    <citation>Li Z, Liu S, Liang X, Wang W, Fei H, Hu P, Chen Y, Xu L, Li R, Shi W. Pulmonary hypertension as an independent predictor of cardiovascular mortality and events in hemodialysis patients. Int Urol Nephrol. 2014 Jan;46(1):141-9. doi: 10.1007/s11255-013-0486-z. Epub 2013 Jun 21.</citation>
    <PMID>23793619</PMID>
  </results_reference>
  <results_reference>
    <citation>Stompór T. An overview of the pathophysiology of vascular calcification in chronic kidney disease. Perit Dial Int. 2007 Jun;27 Suppl 2:S215-22. Review.</citation>
    <PMID>17556308</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>January 16, 2021</last_update_submitted>
  <last_update_submitted_qc>January 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>AMHerez</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>cardiovascular complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

